エストラディオールは,マウスの頸動脈における再エンドセリア化を,エストロゲン受容体-アルファを通して加速するが,エストロゲン受容体-ベータを通じない
L Brouchet1, A Krust, S Dupont
1INSERM U397, Institut L. Bugnard, CHU Rangueil, Toulouse, France.
Circulation
|February 7, 2001
まとめ
17β-エストラジオール (E(2) は,動脈硬化症の予防に重要なプロセスである再エンドセリア化を加速します. この有益な効果は,マウスのERbetaではなく,エストロゲン受容体-α (ERalpha) によって媒介されます.
科学分野:
- 心血管生物学 心血管生物学
- エンドクリノロジー エンドクリノロジー
- 血管生物学 血管生物学
背景:
- 17β-エストラジオール (E(2) は,女性および動物において,アテロプロテクティブ効果を発揮する.
- E(2) は脂質代謝に影響を与え,動脈壁の細胞に直接影響を与えます.
- 研究によると,E(2) は内皮に依存したリラックスと再内皮化を促進する.
研究 の 目的:
- マウスにおけるE(2) 媒介による再エンドセリア化の分子メカニズムを調査する.
- エストロゲン受容体 (ERalphaとERbeta) がE(2) の血管修復への影響を評価する.
主な方法:
- ネズミの電気頸動脈損傷のモデルを開発し,再内皮質形成を評価した.
- カストラされた野生型の雌マウスを使用し,ERalphaまたはERbetaが欠けている卵巣切除されたトランスジェニックマウスを使用しました.
- 投与されたE(2) の内皮再生への影響を評価するために.
主要な成果:
- (2) 野生型のマウスの内皮再生を著しく加速した.
- E(2) は,ERbetaノックアウトマウスにおいて再エンドセリア化を促進した.
- E(2) のプロ再生効果は,ERalphaノックアウトマウスで廃止されました.
結論:
- エストロゲン受容体アルファ (ERalpha) は,E(2) が再エンドセリア化に与える有益な効果の主な媒介である.
- ERalphaは,Eによって動脈硬化症の潜在的な予防に決定的な役割を果たしています.
- ERbetaは,E(2) が再エンドセリア化に及ぼす効果を媒介しているようには見えません.
さらに関連する動画
関連する概念動画
Adrenergic Agonists: Direct-Acting Agents
2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.8K
Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antihypertensive Drugs: Vasodilators
2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
619
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619


